Table 3. Hazard ratios for relapse after treatment response according to the levels of BAFF and APRIL.

			Univariate		Multivariate*
Marker	Group	Level (ng/mL)	HR (95% CI)	P	HR (95% CI)	P
BAFF	1st tertile (n = 24)	0.7 ± 0.12	1 (Reference)		1 (Reference)
	2nd tertile (n = 27)	0.9 ± 0.06	0.59 (0.136–2.523)	0.472	0.85 (0.151–4.796)	0.851
	3rd tertile (n = 28)	1.2 ± 0.26	3.13 (1.016–9.670)	0.047	5.57 (1.394–22.258)	0.015
APRIL	Undetectable (n = 50)	0	1 (Reference)		1 (Reference)
	Low (n = 16)	0.3 (0.07–0.60)	1.37 (0.458–4.091)	0.570	0.96 (0.280–3.299)	0.961
	High (n = 13)	1.6 (1.23–2.93)	1.08 (0.294–3.967)	0.904	0.99 (0.174–5.645)	0.990

^*Adjusted for age, sex, hypertension, diabetes mellitus, baseline creatinine, albumin, cholesterol, urine protein to creatinine ratio, estimated glomerular filtration rate, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, steroids, cyclophosphamides or other immunosuppressive agents, pathologic stage, and tubulointerstitial fibrosis.

Abbreviations: BAFF, B-cell activating factor; APRIL, a proliferation-inducing ligand; HR, hazard ratio; CI, confidence interval.